SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Wilke, AC; Doebele, C; Zindel, A; Lee, KS; Rieke, SA; Ceribelli, M; Comoglio, F; Phelan, JD; Wang, JQ; Pikman, Y; Jahn, D; Haupl, B; Schneider, C; Scheich, S; Tosto, FA; Bohnenberger, H; Stauder, P; Schnutgen, F; Slabicki, M; Coulibaly, ZA; Wolf, S; Bojarczuk, K; Chapuy, B; Brandts, CH; Stroebel, P; Lewis, CA; Engelke, M; Xu, XC; Kim, H; Dang, TH; Schmitz, R; Hodson, DJ; Stegmaier, K; Urlaub, H; Serve, H; Schmitt, CA; Kreuz, F; Knittel, G; Rabinowitz, JD; Reinhardt, HC; Vander Heiden, MG; Thomas, C; Staudt, LM; Zenz, T; Oellerich, T

Oellerich, T (通讯作者)，Goethe Univ, Dept Med 2, Hematol Oncol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.

BLOOD, 2022; 139 (4): 538

Abstract

Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索